Digital Droplet PCR (ddPCR) technology offers precise and highly sensitive detection of rare genetic variants in a quantitative manner. With fast turnaround times, lower costs, and streamlined workflows, ddPCR has become a valuable tool for circulating tumor DNA (ctDNA) analysis. The technology has played a crucial role in development of ctDNA assays for personalized treatment strategies, minimal residual disease (MRD) detection, and longitudinal monitoring of disease progression and relapse. In this workshop session, experts from both academic and commercial laboratories will explore the utility of ddPCR liquid biopsy assays across various cancer types and stages. They will also discuss the practical implementation of these assays in clinical research. Additionally, the session will highlight the diverse range of ddPCR platforms and solutions available for oncology applications.
